首页 Corbus制药控股(usCRBP)-基本信息

Corbus制药控股(usCRBP)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:1.84

最高价:1.86

成交量:2958329.0

昨收价:1.84

最低价:1.73

最新价:1.75

行情图标
概要信息

中文名称:Corbus制药控股


英文名称:Corbus Pharmaceuticals


简介:Corbus制药控股公司(前身为JB Therapeutics公司),根据特拉华州的法律成立于2009年4月24日


电话:1-617-9630100


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Corbus Pharmaceuticals Holdings, Inc.是一家 III 期临床阶段制药公司,专注于开发和商业化治疗炎症和纤维化疾病的新疗法,利用其行业领先的内源性大麻素系统靶向候选药物。Corbus Pharmaceuticals Holdings公司的主要候选产品lenabasum,是一种新型,合成,口服,选择性大麻素受体2型(CB2)激动剂,旨在解决慢性炎症和纤维化过程。Lenabasum目前正在评估系统性硬化症,囊性纤维化,皮肌炎和系统性红斑狼疮。Corbus从Jenrin Discovery LLC获得授权,全球独家开发、生产和销售候选药物,这些药物包括600多种针对内源性大麻素系统的新化合物。Corbus制药控股候选产品还包括: CRB-4001,一种第二代、外周限制性、选择性大麻素受体1型(CB1)反向激动剂,专门用于消除血脑屏障穿透和脑CB1受体占据,介导与第一代CB1反向激动剂相关的神经精神问题。 CRB-4001的潜在适应症包括NASH,原发性胆汁性胆管炎,特发性肺纤维化,放射性肺纤维化,心肌梗塞后的心肌纤维化和急性间质性肾炎等。 CRB-4001计划于2019年进行 I 期临床试验阶段,随后是美国国立卫生研究院(National Institutes of Health,NIH)资助的 II 期研究。

交易日期 交易人 职位 类型 交易份额 价格
2017-08-10 Moran (Sean F) Chief Financial Officer Buy 2500 5.91
2017-08-10 Cohen (Yuval) Chief Executive Officer Buy 1695 6.00
2017-08-10 White (Barbara) Officer Buy 2479 6.05
2017-05-10 Hochman (David P) Director Buy 3400 6.18
2017-05-10 Moran (Sean F) Chief Financial Officer Buy 3300 6.14
2017-05-10 Holmer (Alan F) Director Buy 500 6.23
2017-05-10 Cohen (Yuval) Chief Executive Officer Buy 3250 6.01
2017-05-10 White (Barbara) Officer Buy 2435 6.12
2017-05-10 Catlin (Avery W) Director Buy 5000 6.15
2017-03-16 White (Barbara) Officer Buy 4233 9.49
2017-03-15 Cohen (Yuval) Chief Executive Officer Buy 20000 1.00
2017-03-12 Moran (Sean F) Chief Financial Officer Buy 2000 9.60
2016-12-01 Moran (Sean F) Chief Financial Officer Buy 1500 7.20
2016-11-21 White (Barbara) Officer Buy 1000 7.75
2016-11-21 Cohen (Yuval) Chief Executive Officer Buy 1340 7.64
2016-11-21 Holmer (Alan F) Director Buy 1000 7.49
2016-11-21 Catlin (Avery W) Director Buy 2000 7.55
2016-11-17 Hochman (David P) Director Buy 10000 7.00
2016-09-07 Moran (Sean F) Chief Financial Officer Buy 30800 5.12
2016-08-25 Moran (Sean F) Chief Financial Officer Buy 17900 3.92
2016-08-21 Hochman (David P) Director Buy 1800 3.77
2016-08-17 Moran (Sean F) Chief Financial Officer Buy 65000 3.48
2016-08-16 Moran (Sean F) Chief Financial Officer Buy 83960 3.19
2016-08-16 Cohen (Yuval) Chief Executive Officer Buy 20000 1.00
2016-08-16 White (Barbara) Officer Buy 38000 3.15
2016-06-07 White (Barbara) Officer Buy 1935 3.10
2016-06-05 Cohen (Yuval) Chief Executive Officer Buy 1500 3.34
2016-05-31 White (Barbara) Officer Buy 2570 3.52
2016-05-18 Moran (Sean F) Chief Financial Officer Buy 27250 2.37
2016-05-17 Cohen (Yuval) Chief Executive Officer Buy 2125 2.40
第 页, 共 2 页 首页 上页 下页 末页

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Horizons ETFs Management (Canada) Inc 537225 0.83% 537225 -- 2019-07-31
D. E. Shaw & Co LP 1174551 1.82% 639430 119.49% 2019-03-31
Fidelity Management and Research Company 1204567 1.87% -210000 -14.85% 2019-03-31
FMR Inc 1204567 1.87% -210000 -14.85% 2019-03-31
Vanguard Investments Australia Ltd 1806579 2.80% -- -- 2019-07-31
BlackRock Fund Advisors 2688064 4.17% 12516 0.47% 2019-07-31
Vanguard Group Inc 2859541 4.44% 387708 15.69% 2019-03-31
Knoll Capital Management LP 4985870 7.74% 923079 22.72% 2019-03-31
BlackRock Inc 5030953 7.81% -108940 -2.12% 2019-03-31
Northern Trust Investments Inc 1037330 1.61% 12947 1.26% 2019-07-31
Fidelity SelectCo, LLC 952867 1.48% -184837 -16.25% 2019-07-31
Morgan Stanley - Brokerage Accounts 942508 1.46% 41082 4.56% 2019-03-31
General American Investors Company Inc 557400 0.86% 557400 -- 2019-03-31
Fidelity Management & Research Company 582157 0.90% 39798 7.34% 2019-07-31
BlackRock Advisors LLC 627000 0.97% -- -- 2019-07-31
Northern Trust Investments N A 630089 0.98% 43100 7.34% 2019-03-31
Northern Trust Corp 630089 0.98% 43100 7.34% 2019-03-31
Geode Capital Management, LLC 631874 0.98% -453570 -41.79% 2019-03-31
Morgan Stanley Smith Barney LLC 894307 1.39% 88855 11.03% 2019-03-31
State Street Corporation 931657 1.45% 47542 5.38% 2019-03-31
State Street Global Advisors 501831 0.78% -- -- 2019-06-30
IFP Advisors, Inc 1608569 2.50% 102323 6.79% 2018-12-31
BlackRock Asset Management Canada Ltd 1319109 2.05% 541 0.04% 2019-05-31
ETF Managers Group, LLC 3958561 6.14% 3958561 -- 2018-12-31
Fuller & Thaler Asset Management Inc 262200 0.46% 800 0.31% 2018-12-31
Raymond James Finl Svs Advisors, Inc. 403445 0.70% -24581 -5.74% 2018-09-30
OZ Management LLC 300800 0.53% 300800 -- 2018-09-30
BlackRock Institutional Trust Company NA 1302406 2.28% 68462 5.55% 2018-06-30
Millennium Management LLC 152930 0.27% 152930 -- 2018-06-30
Wyss & Partner Asset Management & Inv AG 105000 0.19% 55000 110.00% 2018-01-31
Allianz Global Investors 137624 0.24% 18778 15.80% 2018-03-31
Renaissance Technologies Corp 166822 0.29% 166822 -- 2018-06-30
Deutsche Bank AG 211718 0.37% 173072 447.84% 2018-06-30
Creative Planning Inc 198635 0.35% 19585 10.94% 2018-03-31
Baker Bros Advisors LP 247450 0.43% -413264 -62.55% 2018-06-30
State Street Corp 797955 1.40% 809 0.10% 2018-06-30
Factor Advisors, LLC 2871052 4.33% 42715 1.51% 2018-09-13
Morgan Stanley & Co Inc 135144 0.24% 15158 12.63% 2018-03-31
Susquehanna Financial Group, LLLP 169692 0.30% 8636 5.36% 2018-03-31
TIAA-CREF Investment Management LLC 124228 0.22% 8572 7.41% 2018-03-31
BNY Mellon Investment Management 134283 0.23% -803 -0.59% 2018-03-31
Jennison Associates LLC 206811 0.36% -18189 -8.08% 2018-03-31
Northern Trust Asset Management 117797 0.21% 863 0.74% 2018-05-31
Susquehanna International Group, LLP 169692 0.30% 8636 5.36% 2018-03-31
Perceptive Advisors LLC 200000 0.36% -214684 -51.77% 2017-12-31
Great Point Partners LLC 600000 1.08% 600000 -- 2017-12-31
Atlantic Trust Group, LLC 143500 0.29% -- -- 2017-09-30
Artal Group S A 150000 0.30% -100000 -40.00% 2017-09-30
Cormorant Asset Management, LLC 2500000 5.60% 500000 25.00% 2016-12-31
Sal. Oppenheim jr. & Cie. AG & Co. KGaA 100000 0.19% 70000 233.33% 2017-03-31
GSA Capital Partners LLP 100800 0.20% 42000 71.43% 2017-09-30
Oppenheim Asset Mgmt Services S.¨¤ r.l. 100000 0.20% -- -- 2017-06-30
Point72 Asset Management, L.P. 189060 0.38% 189060 -- 2017-06-30
Fosun International Ltd 700071 1.59% 700071 -- 2016-09-30
Ghost Tree Capital, LLC 200000 0.45% -100000 -33.33% 2016-09-30
Russell Investment Management Co 99359 0.22% -- -- 2016-12-31
Longwood Capital Partners LLC 81302 0.18% 81302 -- 2016-09-30
Woodstock Corp 55489 0.12% 15558 38.96% 2016-12-31
Lawrence Allen 1523100 4.00% 4843458 0.10% 1999-11-30
Knoll Capital Management 1750000 4.00% 5565000 0.10% 1999-11-30
Mark Tepper 2100400 4.00% 6679272 0.10% 1999-11-30
Sumner Burstein 3824846 4.00% 12163010 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Vanguard Health Care Index Fund 145751 0.23% -1560 -1.06% 2019-06-30
ETFMG Alternative Harvest ETF 7059378 10.95% -- -- 2019-07-31
Vanguard Total Stock Market Index Fund 1806579 2.80% -- -- 2019-06-30
iShares Russell 2000 ETF 1294961 2.01% 2530 0.20% 2019-07-30
Vanguard Extended Market Index Fund 728487 1.13% 1870 0.26% 2019-06-30
iShares Nasdaq Biotechnology ETF 639697 0.99% 9986 1.59% 2019-07-30
BlackRock Health Sciences Opps Port 627000 0.97% -- -- 2019-06-30
iShares Russell 2000 Growth ETF 538046 0.83% -- -- 2019-07-30
Horizons Marijuana Life Sciences ETF 537225 0.83% 537225 -- 2019-06-30
AdvisorShares Pure Cannabis ETF 237478 0.37% -- -- 2019-07-31
NT R2000 Growth Index Fund - Non-Lending 227836 0.35% -9335 -3.94% 2019-06-30
iShares Micro-Cap ETF 150458 0.23% -- -- 2019-07-30
Northern Trust Russell 2000 Index DC NL 157898 0.24% -396 -0.25% 2019-06-30
NT R2000 Growth Index Fund - Lending 165411 0.26% 3342 2.06% 2019-06-30
NT R2000 Index Fund - NL 207989 0.32% 190 0.09% 2019-06-30
Fidelity 217432 0.34% 39522 22.21% 2019-04-30
State Street Russell Small Cap 226331 0.35% -- -- 2019-06-30
State Street Russell Small/Mid Cap 227800 0.35% -- -- 2019-06-30
ALPS Medical Breakthroughs ETF 134917 0.21% -- -- 2019-06-30
iShares US Small Cap ETF (CAD-Hedged) 1123759 1.74% -1890 -0.17% 2019-05-30
Schwab Small Cap Index Fund 110240 0.17% 9313 9.23% 2019-03-31
Russell 2000 Index Non-Lendable Fund E 107517 0.17% 1393 1.31% 2019-03-31
LSF Xantos 105000 0.16% -- -- 2018-11-30
The Vanguard - Russell 2000 Grwth Idx CF 89680 0.14% -89 -0.10% 2019-02-28
AXA 2000 Managed Volatility Portfolio 77998 0.12% -- -- 2019-01-31
TIAA-CREF Small-Cap Blend 73167 0.13% 11364 18.39% 2018-12-31
Vanguard Instl Total Stock Market Idx Fd 69551 0.12% -- -- 2019-01-31
Master Small Cap Index Series 63011 0.11% -- -- 2019-01-31
LVIP SSgA Small Cap Index Fund 59092 0.10% 8304 16.35% 2019-01-31
iShares Russell 2000 Small-Cap Index Fd 63011 0.11% 5756 10.05% 2018-12-31
Bridgeway Ultra Small Company Market Fd 125915 0.22% 125915 -- 2018-09-30
Virtus LifeSci Biotech Clinical Trls ETF 71574 0.13% -- -- 2018-11-30
Fidelity Advisor 184837 0.32% -836184 -81.90% 2018-07-31
AdvisorShares Vice ETF 78070 0.14% -- -- 2018-10-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 82400 0.14% -- -- 2018-07-31
Tierra XP Latin America Real Estate ETF 2871052 4.33% 42715 1.51% 2018-09-13
Vanguard Total Stock Mkt Idx 1312967 2.30% 26353 2.05% 2018-07-31
Vanguard Extended Market Idx Inv 666635 1.17% -- -- 2018-07-31
iShares Nasdaq Biotechnology 641022 1.00% -1221 -0.19% 2018-09-12
BlackRock Health Sciences Opps Inv A 559900 0.98% 559900 -- 2018-07-31
iShares Russell 2000 Growth 472393 0.73% -456 -0.10% 2018-09-12
State Street Russell Small/Mid Cap Idx Fd Cl I 136600 0.27% 136600 -- 2017-06-30
iShares Micro-Cap 133248 0.21% -- -- 2018-09-12
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 121474 0.21% -648 -0.53% 2018-07-31
Vanguard Health Care ETF 97705 0.17% 828 0.85% 2018-07-31
Fidelity Spartan 97055 0.17% -- -- 2018-07-31
BlackRock Extended Equity Market K 96862 0.17% 31958 49.24% 2018-06-30
Schwab Small Cap Index 94500 0.17% -- -- 2018-07-31
The Vanguard Russell 2000 Growth Index 88318 0.15% -- -- 2018-07-31
BioShares 80342 0.13% -- -- 2018-09-07
CREF Stock R1 91400 0.16% -- -- 2018-04-30
BlackRock Russell 2000 66477 0.12% 628 0.95% 2018-03-31
AXA 2000 Managed Volatility K 66668 0.12% -- -- 2018-03-31
Russell US Small Cap Equity I 99359 0.22% -- -- 2016-12-31
Vanguard Balanced Index Inv 27092 0.06% -- -- 2016-12-31
BNY Mellon EB DL Mkt Completion 17898 0.04% -1243 -6.49% 2016-12-31
The Vanguard Total Stock Market Index 9187 0.02% -- -- 2016-12-31
iShares Core S&P Total US Stock Mkt 9546 0.02% -- -- 2017-02-07
Master Extended Market Index Series 6152 0.01% -- -- 2016-12-31
AXA/Lord Abbett Micro Cap K 6590 0.01% -- -- 2016-11-30
SSgA U.S. Total Market Index Fd Class I 5823 0.01% 5823 -- 2016-09-30
BlackRock Extended Equity Market Fund 19251 -- 19251 -- 2015-09-30
Fidelity® NASDAQ Composite Index® Fund 14493 -- 14493 -- 2015-09-30
The Vanguard - Total Stk Mkt Idx Trust. CF 8700 -- -- -- 2015-10-31
Vanguard US Equity Index 3900 -- -- -- 2015-07-31
AXA/Lord Abbett Micro Cap Portfolio 3102 -- -- -- 2015-09-30
Fidelity Spartan® Extended Mkt Indx Fd 76742 0.20% 37545 95.80% 2015-09-30

Yuval Cohen Founder of Celsus Therapeutics Plc, Yuval Cohen is Chief Executive Officer & Director at Corbus Pharmaceuticals Holdings, Inc. and Chief Executive Officer for Corbus Pharmaceuticals, Inc. (a subsidiary of Corbus Pharmaceuticals Holdings, Inc.). He previously occupied the position of Director & Senior Vice President at Celsus Therapeutics Plc. He received an undergraduate degree from the University of Cape Town and a doctorate from the University of Paris V.
Alan F. Holmer Currently, Alan F. Holmer occupies the position of Chairman of Corbus Pharmaceuticals Holdings, Inc. and Chairman of Corbus Pharmaceuticals, Inc. (a subsidiary of Corbus Pharmaceuticals Holdings, Inc.). He is also on the board of Food for the Hungry, Inc. In the past he was Counsel at Smith, Currie & Hancock LLP, Associate for Steptoe & Johnson LLP, Partner at Sidley & Austin, President & Chief Executive Officer for Pharmaceutical Research & Manufacturers of America and Chairman-Metropolitan Washington at The Cystic Fibrosis Foundation, Inc. Alan F. Holmer received an undergraduate degree from Princeton University and a graduate degree from Georgetown University Law Center.
Avery W. Catlin Avery W. Catlin is on the board of Corbus Pharmaceuticals Holdings, Inc. and Provention Bio, Inc. and Vice President at CuraGen Corp. He previously occupied the position of Chief Financial Officer for Repligen Corp., CFO, Secretary, Treasurer & Senior Vice President at Celldex Therapeutics, Inc. and Chief Financial Officer, Secretary & SVP at AVANT Immunotherapeutics, Inc. (a subsidiary of Celldex Therapeutics, Inc.), Chief Financial Officer & VP-Operations at Endogen, Inc. and Chief Financial Officer of MediSense, Inc. Avery W. Catlin received an undergraduate degree from the University of Virginia and an MBA from Babson College.
Sean F. Moran Presently, Sean F. Moran is Chief Financial & Accounting Officer of Corbus Pharmaceuticals Holdings, Inc. and Chief Financial Officer of Corbus Pharmaceuticals, Inc. (a subsidiary of Corbus Pharmaceuticals Holdings, Inc.). Mr. Moran is also on the board of Video Advertising Bureau. In his past career he occupied the position of Chief Financial Officer at Anika Therapeutics, Inc., Chief Financial Officer of Satcon Technology Corp., Chief Financial Officer & Senior Vice President at Celsion Corp., Chief Financial Officer at Echo Therapeutics, Inc. and Chief Financial Officer of Sontra Medical Corp. (a subsidiary of Echo Therapeutics, Inc.), Chief Financial Officer of Invivo Therapeutics Holdings Corp. and Chief Financial Officer at InVivo Therapeutics Corp. (a subsidiary of Invivo Therapeutics Holdings Corp.), Chief Financial Officer at Transport Pharmaceuticals, Inc. and Executive Vice President-Brand Sales at Viacom Media Networks, Inc. Mr. Moran received an undergraduate degree and an MBA from Babson College.
David P. Hochman Founder of 6 different companies, which include: OPKO Biologics Ltd., BackBeat Medical, Inc. and Caliber Therapeutics, Inc. David P. Hochman is an entrepreneur and businessperson who has been at the head of 9 different companies and is Chairman & Chief Executive Officer for Orchestra BioMed, Inc., Chairman of Motus GI Holdings, Inc., President & Director at Mollie Parnis Livingston Foundation, Inc., President for Accelerated Technologies, Inc. (Texas) and President at Accelerated Technologies, Inc. David P. Hochman is also on the board of Aids Action Foundation, Corbus Pharmaceuticals Holdings, Inc. and Adgero Biopharmaceuticals Holdings, Inc. In the past Mr. Hochman was Chairman for Vital Access Corp., President & Director at BackBeat Medical, Inc. (he founded the company in 2009), Advisor at Idera Pharmaceuticals, Inc., Managing Partner at Orchestra Medical Ventures LLC, Chairman at Motus G.I. Medical Technologies Ltd., Chief Executive Officer for Spencer Trask Edison Partners LLC, Advisor at Health Dialog Services Corp., Managing Director at Augment Securities, Inc., Director at OPKO Biologics Ltd., Director at Caliber Therapeutics, Inc. and Director at FreeHold Surgical, Inc. David P. Hochman received an undergraduate degree from the University of Michigan.
Barbara White Currently, Barbara White is Chief Medical Officer for Corbus Pharmaceuticals Holdings, Inc. and Chief Medical Officer of Corbus Pharmaceuticals, Inc. (a subsidiary of Corbus Pharmaceuticals Holdings, Inc.). In her past career Dr. White held the position of Associate Chief of Staff at Baltimore VA Medical Center, Head-Research & Development at Stiefel Research Institute, Inc., Vice President-Clinical Development at MedImmune LLC and Professor & Vice Chairman-Research Department at the University of Maryland School of Medicine. Dr. White received a doctorate from Perelman School of Medicine.
David P. Hochman Founder of 6 different companies, which include: OPKO Biologics Ltd., BackBeat Medical, Inc. and Caliber Therapeutics, Inc. David P. Hochman is an entrepreneur and businessperson who has been at the head of 9 different companies and is Chairman & Chief Executive Officer for Orchestra BioMed, Inc., Chairman of Motus GI Holdings, Inc., President & Director at Mollie Parnis Livingston Foundation, Inc., President for Accelerated Technologies, Inc. (Texas) and President at Accelerated Technologies, Inc. David P. Hochman is also on the board of Aids Action Foundation, Corbus Pharmaceuticals Holdings, Inc. and Adgero Biopharmaceuticals Holdings, Inc. In the past Mr. Hochman was Chairman for Vital Access Corp., President & Director at BackBeat Medical, Inc. (he founded the company in 2009), Advisor at Idera Pharmaceuticals, Inc., Managing Partner at Orchestra Medical Ventures LLC, Chairman at Motus G.I. Medical Technologies Ltd., Chief Executive Officer for Spencer Trask Edison Partners LLC, Advisor at Health Dialog Services Corp., Managing Director at Augment Securities, Inc., Director at OPKO Biologics Ltd., Director at Caliber Therapeutics, Inc. and Director at FreeHold Surgical, Inc. David P. Hochman received an undergraduate degree from the University of Michigan.
Yuval Cohen Founder of Celsus Therapeutics Plc, Yuval Cohen is Chief Executive Officer & Director at Corbus Pharmaceuticals Holdings, Inc. and Chief Executive Officer for Corbus Pharmaceuticals, Inc. (a subsidiary of Corbus Pharmaceuticals Holdings, Inc.). He previously occupied the position of Director & Senior Vice President at Celsus Therapeutics Plc. He received an undergraduate degree from the University of Cape Town and a doctorate from the University of Paris V.
Craig Millian Craig Millian is Chief Commercial Officer of Corbus Pharmaceuticals Holdings, Inc. In his past career Mr. Millian occupied the position of Senior Vice President-Neurology & Immunology at EMD Serono, Inc. Mr. Millian received an undergraduate degree from the University of Pennsylvania and an MBA from New York University.
Paris Panayiotopoulos Founder of Anthos Therapeutics, Inc., Paris Panayiotopoulos currently is Executive Chairman for Genevant Sciences Corp. and Operating Partner at Clarus Ventures LLC. He is also on the board of The Medicines Co., European Pharmaceutical Market Research Association, Corbus Pharmaceuticals Holdings, Inc. and Anthos Therapeutics, Inc. and Member of Chamber of Commerce of The United States of America. In the past Paris Panayiotopoulos occupied the position of Head-Western Europe at Merck KGaA President & Managing Director at EMD Serono, Inc. and President at Merck Serono Co., Ltd. (both are subsidiaries of Merck KGaA), President, Chief Executive Officer & Director at ARIAD Pharmaceuticals, Inc. and Principal at Eli Lilly & Co. Ltd. He received a graduate degree from Cranfield School of Management and an undergraduate degree from University College London.
Robert Discordia Robert Discordia is VP-Pharmaceutical Development & Manufacturing at Corbus Pharmaceuticals Holdings, Inc. He received a doctorate from Syracuse University and an undergraduate degree from State University of New York College at Cortland.
Ross Lobell Presently, Ross Lobell is Vice President-Regulatory Affairs for Corbus Pharmaceuticals Holdings, Inc. Mr. Lobell received an undergraduate degree from Lebanon Valley College.
John Kenneth Jenkins John Kenneth Jenkins is on the board of Corbus Pharmaceuticals Holdings, Inc. and Principal-Drug & Biological Products at Www Greenleafhealthllc Com. In his past career Dr. Jenkins held the position of Director-New Drugs at Center for Drug Evaluation & Research and Assistant Professor at Virginia Commonwealth University Health System. He received a doctorate from the University of Tennessee.
Sergei Atamas Currently, Sergei Atamas holds the position of Executive Director-Research at Corbus Pharmaceuticals Holdings, Inc.
Rachelle Jacques Currently, Rachelle Jacques is Chief Executive Officer of Enzyvant, Inc. She is also on the board of Corbus Pharmaceuticals Holdings, Inc. In her past career Ms. Jacques held the position of Senior Vice President-Global Complement Franchise at Alexion Pharmaceuticals, Inc., Vice President-U S Hematology Marketing at Shire Plc and Vice President of Business Operations at Baxalta, Inc. Ms. Jacques received an undergraduate degree from Alma College.

量化对比

全部评论 1

  • 美股抗疫概念股盘前走强,阿索尔达生物制药涨超110%,克利夫兰生物实验室涨36%,Corbus Pharmaceuticals涨近5%,Moderna涨近3%。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐